Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $215.50 -1.62%
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $1.99, $0.38 better than the analyst estimate of $1.61. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.21 billion.
GUIDANCE:
Biogen sees FY2026 EPS of $15.25-$16.25, versus the consensus of $14.92.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Empire Petroleum (EP) files $150M mixed shelf
- Lockheed Martin wins $871 million F-35 contract modification
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
